Tags: Drug.
Simeprevir (formerly TMC435; trade name Olysio) is a drug for the treatment and cure of hepatitis C. It was developed by Medivir and Johnson & Johnson’s pharmaceutical division Janssen Pharmaceutica. In the United States simeprevir is approved by the Food and Drug Administration for use in combination with peginterferon-alfa and ribavirin for hepatitis C and hepatitis B Simeprevir has been approved in Japan for the treatment of chronic hepatitis C infection genotype 1.
